These 19 projects, which would cost Rs 1650 crore, are expected to create 4500 plus employment opportunities across sectors like plastic, seafood processing, manufacturing, tourism, IT and ESDM, refractory, agro and food processing, pharmaceuticals and steel downstream.
New Delhi [India], February 7 (ANI/PNN): Ajay Kakar is now a name to reckon with. He was recently awarded as the most promising entrepreneur by non-other than the Economic Times. His vision, his dedication and his business acumen has taken Salve Pharma to the next level, in a very short span
Hyderabad (Telangana) [India], February 1 (ANI/NewsVoir): Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the third quarter of the financial year 2023 ended December 31, 2022.
The product will be manufactured at Granules manufacturing facility in Chantilly, Virginia, and is expected to be launched shortly, according to a company statement shared with stock exchanges.
It is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute IV injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The Central government has approved the proposal of the Pharmaceuticals and Medical Devices Bureau of India (PMBI) to invite online applications for the opening of new Jan Aushadhi Kendras in 651 districts of different states and union territories.
New Delhi [India], January 4 (ANI/PNN): Niner Pharmaceuticals LLC, a UAE-based pharmaceutical company, plans to develop an end-to-end supply chain between the Indian market and the GCC markets. With this aim, the company is investing in the Indian market by assembling world-class manufacturi
According to the statement, both firms would collaborate for green molecule solutions and its wider applications in pharmaceuticals to build a leadership position. Granules also said it would develop a facility at Kakinada in Andhra Pradesh with an estimated cost of Rs 2,000 crore over five
Mumbai (Maharashtra)/ New Delhi [India], January 3 (ANI/BusinessWire India): Cyril Amarchand Mangaldas advised the promoters of Suven Pharmaceuticals Limited (Suven Pharmaceuticals) in relation to the acquisition of Suven Pharmaceuticals by global private equity firm Advent, for an aggregate
As part of the transaction, Advent said it would also be making an open offer to acquire additional 26 per cent of the outstanding equity shares of the company from the public shareholders.